Malignant pleural mesothelioma: an update on diagnosis and treatment options (Q34513958)

1 July 2018

title

Malignant pleural mesothelioma: an update on diagnosis and treatment options (English)

1 reference

1 July 2018

malignant pleural mesothelioma

main subject

1 reference

3

1 reference

1 July 2018

author name string

Sanjana Kondola

series ordinal

1

1 reference

1 July 2018

David Manners

series ordinal

2

1 reference

1 July 2018

publication date

12 February 2016

1 reference

1 July 2018

Therapeutic advances in respiratory disease

published in

1 reference

1 July 2018

volume

10

1 reference

1 July 2018

issue

3

1 reference

1 July 2018

page(s)

275-288

1 reference

1 July 2018

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

FDG PET/CT in the management of primary pleural tumors and pleural metastases.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Molecular pathogenesis of malignant mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Asbestos use and asbestos‐related diseases in Asia: Past, present and future

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Hallmarks of Cancer: The Next Generation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Mesothelin targeted cancer immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Heat shock protein 90: the cancer chaperone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

The role of radiation therapy in malignant pleural mesothelioma: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Advances in malignant mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Multimodality Management of Malignant Pleural Mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

CT in differential diagnosis of diffuse pleural disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Radiographic chest assessment of lung injury following hemithorax irradiation for pleural mesothelioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma

7 July 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

A Diagnostic Assay Based on MicroRNA Expression Accurately Identifies Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Malignant mesothelioma in Australia, 1945-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

The MARS feasibility trial: conclusions not supported by data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5933604

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

27 October 2018

1 reference

https://api.crossref.org/works/10.1177/1753465816628800

Staging of malignant pleural mesothelioma: comparison of CT and MR imaging

21 January 2018

1 reference

12 December 2020

Deterioration in lung function following hemithorax irradiation for pleural mesothelioma

1 reference

12 December 2020

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer a

1 reference

12 December 2020

The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma

1 reference

12 December 2020

Pleuropneumonectomy in the treatment of malignant pleural mesothelioma

1 reference

12 December 2020

Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis

1 reference

12 December 2020

Multimodality Therapy for Malignant Pleural Mesothelioma

1 reference

12 December 2020

Asbestos exposure, pleural mesothelioma, and serum osteopontin levels

1 reference

12 December 2020

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

12 December 2020

Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience

1 reference

12 December 2020

A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit

1 reference

12 December 2020

Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma

1 reference

12 December 2020

Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma

1 reference

12 December 2020

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

1 reference

12 December 2020

Identifiers

DOI

10.1177/1753465816628800

1 reference

1 July 2018

PMC publication ID

5933604

1 reference

1 July 2018

PubMed publication ID

26873306

1 reference

1 July 2018